MarkSDeguentherMD

Urology • Homewood, AL

Physician

Join to view full profile

Dr. Deguenther is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Deguenther's full profile

Already have an account?

Office
3485 Independence Dr
Homewood, AL 35209
Phone+1 205-930-0920

Fax+1 205-445-0115

Education & Training

University of TennesseeResidency, Urology, 1991 - 1995
University of TennesseeResidency, Surgery, 1989 - 1991
Medical College of Georgia at Augusta UniversityClass of 1989

Certifications & Licensure

AL State Medical License 1995 - 2024
TN State Medical License 1990 - 1995
American Board of Urology Urology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification PrimeSUITE EHR, Greenway Health, LLC, 2012-2013

Clinical Trials

Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG Start of enrollment: 2015 Aug 01
Completed
Phase 3
Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients Start of enrollment: 2016 Dec 01
Completed
Phase 1
Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer Start of enrollment: 2017 Sep 26
Completed
Phase 3

Publications & Presentations

PubMed

4 citations
A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients
Neal D. Shore, Ivan Mincik, Mark DeGuenther, Vladimir Student, Mindaugas Jievaltas
World Journal of Urology. 2020-01-01
15 citations
Self-Identified African Americans and prostate cancer risk: West African genetic ancestry is associated with prostate cancer diagnosis and with higher Gleason sum on b...
William E. Grizzle, Rick A. Kittles, Soroush Rais-Bahrami, Ebony Shah, George W. Adams
Cancer Medicine. 2019-11-01
39 citations
Two-Year Outcomes After Aquablation Compared to TURP: Efficacy and Ejaculatory Improvements Sustained
Peter J. Gilling, Neil Barber, Mohamed Bidair, Paul Anderson, Mark A. Sutton
Advances in Therapy. 2019-04-26

Journal Articles

Symptom Relief and Anejaculation After Aquablation or TURP: Subgroup Analysis from a Blinded Randomized Trial
Alexis E Te, Mark Plante, Barrett Cowan, Claus Roehrborn, Mohamed Bidair, Leo Doumanian, Andrew Arther, Gopal Badlani, Mark DeGuenther, Mark Sutton, BJU International